Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The Trump administration is preparing to launch a new investigation under Section 301 of the Trade Act of 1974 to determine ...

Vertex Pharmaceuticals (VRTX) shares have been fairly steady recently, as investors digest the company’s financial ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $416.81, demonstrating a +2.01% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's ...

For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $407.9, denoting a -1.05% move from the preceding trading day.

Vertex Pharmaceuticals Incorporated has recently witnessed a notable change in its stock holdings, with Aberdeen Group plc ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals has been a clear winner in the pharmaceutical sector. Over the past two decades, this powerhouse has ...

Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades ...

Investing.com -- Stoke Therapeutics (NASDAQ:STOK) stock rose 7% Monday after the company announced the appointment of Ian F. Smith as its permanent Chief Executive Officer.